About
9
Publications
366
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
27
Citations
Current institution
Publications
Publications (9)
Background
Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the preferred surgical option for refractory ulcerative colitis (UC), dysplasia, or malignancy. De novo Crohn’s Disease (CD) is a recognized postoperative complication that can occur in UC patients after IPAA. Pouchitis, a common complication marked by nonspecific po...
Objective:
Vascular involvement is an important cause of morbidity and mortality in patients with Behçet's syndrome (BS). We aimed to survey the efficacy and safety of infliximab (IFX) in BS patients with vascular involvement followed in a dedicated tertiary center.
Methods:
Charts of all BS patients who used IFX for vascular involvement between...
Background
Vascular involvement is the most common cause of mortality and an important cause of disability in patients with Behçet’s syndrome (BS). Cyclophosphamide has been the treatment choice for severe vascular involvement, but high frequency of adverse events such as infertility and infections cause concern. TNF inhibitors can be an alternativ...
Background
Infliximab (IFX) is an effective therapeutic option in the management of severe and refractory manifestations of Behçet’s syndrome (BS).
Objectives
We aimed to evaluate long term drug survival of IFX in a large cohort of BS patients.
Methods
We reviewed the charts of BS patients who received IFX between 2004 and June 2021 and noted dem...
Objectives
Infliximab (IFX) is being increasingly used for the treatment of severe manifestations of Behçet syndrome (BS). However, emergence of new manifestations has also been occasionally reported during IFX treatment. We aimed to assess the frequency of new manifestations in our BS patients treated with IFX.
Methods
A chart review was conducte...
Background
Infliximab (IFX) plays a key role in the management of severe and refractory manifestations of Behçet syndrome (BS). However we had previously shown that its sustained use may be limited due to adverse events and lack of patient compliance (1).
Objectives
To assess the retention rate of IFX, adverse events, causes of discontinuation and...
Background
Infliximab (IFX) is increasingly used in the management of severe, relapsing or refractory manifestations of Behçet Syndrome (BS). Emergence of de novo manifestations have been reported during IFX treatment, despite efficacy for the initial manifestation that required IFX use ¹ .
Objectives
We aimed to survey a sizeable cohort of BS pat...
Background
Vascular involvement is an important cause of morbidity and mortality in patients with Behçet syndrome (BS). TNF inhibitors have been reported to be effective for almost all serious manifestations of BS but data on vascular involvement is still limited.
Objectives
To survey the efficacy and safety of infliximab (IFX) in BS patients with...
Background
Infliximab (IFX) has become an important treatment option for all manifestations of Behçet syndrome (BS). Adverse events, loss of efficacy, lack of patient compliance and cost may limit its sustained use in patients with BS.
Objectives
We aimed to evaluate the drug retention rates, causes of discontinuation and outcome after cessation o...
